Journal article

Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status

NC Murphy, AV Biankin, EKA Millar, CM McNeil, SA O'Toole, D Segara, P Crea, MA Olayioye, CS Lee, SB Fox, AL Morey, M Christie, EA Musgrove, RJ Daly, GJ Lindeman, SM Henshall, JE Visvader, RL Sutherland

International Journal of Cancer | WILEY | Published : 2010

Abstract

The phospholipid transfer protein STARD10 cooperates with c-erbB signaling and is overexpressed in Neu/ErbB2 breast cancers. We investigated if STARD10 expression provides additional prognostic information to HER2/neu status in primary breast cancer. A published gene expression dataset was used to determine relationships between STARD10 and HER2 mRNA levels and patient outcome. The central findings were independently validated by immunohistochemistry in a retrospective cohort of 222 patients with breast cancer with a median follow-up of 64 months. Kaplan-Meier and Cox proportional hazards analyses were used for univariate and multivariate analyses. Patients with low STARD10 or high HER2 tumo..

View full abstract